Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 2/20 | 0.33 |
| ▸ | ACP1 | P24666 | 1/20 | 0.33 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.32 |
| ▸ | SELE | P16581 | 1/20 | 0.32 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.31 |
| ▸ | LOX | P28300 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.31 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6136788 | 0.86 | CYP11B1 (0.38) | PDE4DP2RX7LOXAOC3 | |
| SCHEMBL16213010 | 0.85 | CYP11B1 (0.31) | — | |
| SCHEMBL321133 | 0.79 | PDXK (0.40) | PDE4DACP1ICAM1SELEVCAM1 | |
| SCHEMBL17048782 | 0.75 | TAAR1 (0.56) | TAAR1GAA | |
| SCHEMBL18814185 | 0.75 | ALDH1A1 (0.34) | PDE4DAOC3TAAR1GAA | |
| SCHEMBL17056904 | 0.75 | PDE4D (0.30) | PDE4DTAAR1GAA | |
| SCHEMBL6514186 | 0.75 | PDE4D (0.30) | PDE4DTAAR1GAA | |
| SCHEMBL13059193 | 0.75 | PDE4D (0.33) | PDE4DACP1ICAM1SELEVCAM1 | |
| SCHEMBL908383 | 0.72 | TAAR1 (0.58) | TAAR1GAA | |
| SCHEMBL3415768 | 0.72 | ALDH1A1 (0.43) | GAAPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021138391-A1 | INDAZOLE COMPOUNDS | TYRA BIOSCIENCES, INC. (US) | 2021-07-08 | — | — | WO | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3110810-B1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LTD (JP) | 2018-05-02 | — | — | EP | disclosed |
| EP-3110810-A1 | PYRAZOLE AMIDE DERIVATIVE | Teijin Pharma Limited (JP) | 2017-01-04 | — | — | EP | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365522-B2 | Pyrazole amide derivative | AMGEN INC. (US) | 2016-06-14 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| US-20150266824-A1 | Pyrazole Amide Derivative | TEIJIN LIMITED (JP) | 2015-09-24 | — | — | US | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| WO-2015129926-A1 | PYRAZOLE AMIDE DERIVATIVE | TEIJIN PHARMA LIMITED (JP) | 2015-09-03 | — | — | WO | disclosed |
| EP-2625175-A1 | CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR | Eli Lilly and Company (US) | 2013-08-14 | — | — | EP | disclosed |
| WO-2012047699-A1 | CRYSTALLINE (R) - (E) -2- (4- (2- (5- (1- (3, 5 -DICHLOROPYRIDIN-4 -YL) ETHOXY) - 1H - INDAZOL - 3 - YL) VINYL) -1 H- PYRAZOL- 1 -YL) ETHANOL AND ITS USE AS FGFR INHIBITOR | ELI LILLY AND COMPANY (US) | 2012-04-12 | — | — | WO | disclosed |
| EP-2427449-A1 | VINYL INDAZOLYL COMPOUNDS | Eli Lilly and Company (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129509-A1 | VINYL INDAZOLYL COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266824-A1 | Pyrazole Amide Derivative | RORC, RORB, RORA | PDE4D 1932/4885ACP1 2272/4885ICAM1 3399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.